BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 StudyDavid Lavie,Vincent Ribrag, Michael Loschi,Costas K. Yannakou, Maan Alwan, Adi Schacham Abulafia,Jesús María Hernández-Rivas,Yulia Volchek,Chun Yew Fong,Massimiliano Bonifacio,Jean-Jacques Kiladjian,Jean-Christophe Ianotto,Valentín García Gutiérrez,Alessandra Tucci,Blanca Xicoy,Haifa Kathrin Al-Ali,Moshe Talpaz,Jonathan M. Gerber,Indu Raman,Ciprian TomuleasaBlood（2023）引用 0|浏览12暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
